Ruxolitinib
A JAK1/JAK2 inhibitor used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, and as a topical cream for atopic dermatitis and vitiligo. It reduces the overactive inflammatory signaling pathway that drives these conditions.
Molekularmasse
306,4000 g/mol
LogP
2,10
TPSA
83,20 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D-Struktur
Cite this structure
Embed this structure
SMILES
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
InChI
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
Molecular Formula
C17H18N6
HBD / HBA
1 / 4
Rotierbare Bindungen
4
Schwere Atome
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A JAK1/JAK2 inhibitor used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, and as a topical cream for atopic dermatitis and vitiligo. It reduces the overactive inflammatory signaling pathway that drives these conditions.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Ruxolitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1789941. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25126798. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ruxolitinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ruxolitinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ruxolitinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ruxolitinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ruxolitinib"></drugfyi-drug>